Dicerna Pharmaceuticals, developing treatments for disease that silence genes by interfering with their RNA instructions, is licensing its technology to drug maker Eli Lilly and Co . . . → Read More: Gene Silencing Technology Licensed in $3.7B Deal
|
|||||
 Comments are closed  Intellectual property, Joint ventures/collaborations  biomedical, biotechnology, equity, genomics, investment, licensing, life sciences, pharmaceuticals 
The global chemical company BASF is licensing a more precise form of genome editing from the Broad Institute, a genetics research center affiliated with Harvard University and MIT. . . . → Read More: BASF Licensing Precise Crispr Editing from Broad Institute One comment - (Comments are closed) Intellectual property agriculture, biomedical, biotechnology, chemistry, Europe, genomics, licensing, manufacturing, patent, physical sciences, university 
A company in Maryland developing alternatives to human organ transplants is licensing a technology to help create 3-D printed lungs for transplantation with bioinks derived from tobacco plants. . . . → Read More: Licensing Deal for Bioinks in 3-D Printed Transplant Lungs One comment - (Comments are closed) Intellectual property, New products agriculture, biomedical, biotechnology, engineering, entrepreneurs, Israel, licensing, life sciences, materials science, medical device, physical sciences, university 
Drug maker AbbVie and biotechnology company Morphic Therapeutic are collaborating on new treatments for fibrosis based on Morphic’s technology blocking proteins that promote fibrosis. . . . → Read More: Harvard Spin-Off, AbbVie Partner on Fibrosis Treatments One comment - (Comments are closed) Intellectual property, New products biomedical, biotechnology, licensing, life sciences, pharmaceuticals, preclinical, university 
A document with standard legal language for terms and conditions of sharing biotechnology materials is now available for academic and industry research labs. . . . → Read More: Model Biotech Materials Sharing Agreement Unveiled Comments are closed Intellectual property, Joint ventures/collaborations biomedical, biotechnology, life sciences, NIH, standard, U.K., university 
A start-up enterprise founded by medical researchers in the U.S. and Europe is developing treatments for cancer and autoimmune disorders that change chemical reactions in immune system cells. . . . → Read More: Start-Up Developing Immunometabolism Therapies, Gains $30M Funding Comments are closed Finance, Intellectual property biomedical, biotechnology, cancer, chemistry, entrepreneurs, equity, Europe, investment, licensing, life sciences, pharmaceuticals, physical sciences, university, venture capital 
A biotechnology company developing therapies that silence the actions of disease-causing genes is licensing its treatment program for hepatitis-B to Janssen Pharmaceuticals. . . . → Read More: Biotech in $3.7B Licensing Deal for Hepatitis-B One comment - (Comments are closed) Finance, Intellectual property biomedical, biotechnology, clinical trials, equity, genomics, investment, licensing, life sciences, pharmaceuticals 
A company developing treatments for heart disease using stem cells to regenerate healthy heart tissue received two new patents for techniques supporting its core processes. . . . → Read More: Patents Awarded for Stem Cell Heart Disease Technologies Comments are closed Intellectual property biomedical, clinical trials, engineering, heart disease, life sciences, medical device, patent, pharmaceuticals, stem cells, USPTO
Biopharmaceutical company Gilead Sciences is acquiring a genome-editing technology for treating hepatitis-B, a viral disease affecting the liver. . . . → Read More: Gilead Gains Genome-Editing Hepatitis B Therapy Comments are closed Intellectual property, Joint ventures/collaborations biomedical, biotechnology, genomics, licensing, life sciences, pharmaceuticals, preclinical 
A U.S. appeals court supported the Broad Institute’s claims it invented a separate Crispr technology from University of California, affirming a previous U.S. patent office ruling. . . . → Read More: Appeals Court Backs Broad Institute in Crispr Case Comments are closed Intellectual property agriculture, biomedical, entrepreneurs, genomics, licensing, life sciences, patent, pharmaceuticals, university, USPTO |
One Blood Test Fits All Diseases A Thinking Person’s Artificial Intelligence Do You Want Your Bacon CRISPR? Health Care, Precisely One Person at a Time Let Guinea Pigs be Guinea Pigs Look Out Pharma. The Tech Industry is After You |
||||
|
Copyright © 2018 Technology News and Literature - All Rights Reserved Powered by WordPress & Atahualpa |
|||||
